Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
are assessed based on the CT attenuation coefficient (measured in Hounsfield units, HU) or only the enhancing area is incorporated into the changes in the response evaluation (17) . These new criteria are reliable response evaluation methods for molecularly targeted agents, and radiologists need to evaluate changes in internal tumor attenuation for evidence of residual disease to determine if further treatment is required. Despite previous studies in which tumor attenuation changes of GISTs treated by imatinib were discussed, the correlation between CT and pathological findings are not fully understood, and only been a few incidental reports are available about the pathological changes underlying the CT attenuation of treated GISTs.
The purpose of this study was to investigate the correlation between changes in CT attenuation and GIST pathology after imatinib treatment and to present the pathological rationale for new proposed CT response criteria.
MATERIALS AND METHODS

Patients
The Institutional Review Board of both institutions approved this retrospective study, and the requirement for informed con- patients had a single metastatic GIST (eight had tumors in the peritoneum, six had tumors in the liver, and one each had tumors in the small bowel, spleen, pelvic soft tissue, and mediastinum) ( Table 1 ). The mean interval between initial imatinib treatment and the final follow-up CT before surgery was about 15 months. All patients underwent surgical resection within 2 months after the final follow-up CT. The electronic medical records of each patient were reviewed to establish the imatinib prescription.
attenuation on contrast-enhanced computed tomography (CT) scans after imatinib treatment of a GIST, although the anatomical change (e.g., tumor size) was initially minor (11) . Therefore, anatomic tumor response metrics can be misleading when applied to this molecular-targeted therapy. The Response Evaluation Criteria in Solid Tumor (RECIST) criteria, based on the sum of the longest diameters of the target lesions in the transverse plane, is the most widely used measurement system in clinical trials (12) . However, a number of studies have shown that RECIST is inadequate for evaluating tumors treated with molecularly targeted drugs or locoregional therapies (13) (14) (15) .
Thus, several CT response criteria, such as the "Choi response criteria" (13) (14) (15) and the "modified RECIST (mRECIST) criteria" (16) have been proposed. Tumor changes in these criteria 
RESULTS
Clinical Features
All patients were administered a 400 mg oral dose of imatinib daily beginning in July 2009. The dose was reduced to 300 mg for 1 month in two patients due to a drug eruption; and administration of the drug was discontinued for 3 months in another patient due to cost. All other patients were treated continuously until surgery. Each patient underwent a baseline CT scan before starting imatinib treatment and a follow-up CT scan just prior to surgical resection. The mean interval between the initial prescription of imatinib and curative resection was 17.3 months (range, 3-44 months).
CT Findings
All surgically resected tumors were identified on CT scans. showed PD based on RECIST 1.1 (Table 3) .
We also assessed the correlation between secondary histopathological findings according to the duration of imatinib treatment and the resected tumor site (Table 4) The other four contained viable hypercellular areas with hyalinization and hemorrhagic necrosis but no cystic degeneration (Table 3) . Finally, the histopathological features of the posttreatment GISTs were subdivided into five types.
Correlation between CT and Histopathological
Findings
The CT attenuation values before and after imatinib treat- (Table 3) . Six of these tumors (30%) exhibited cystic degeneration (Fig. 1) , six (30%) showed hemorrhagic necrosis, six (30%) showed hyalinization (Figs. 2, 3 ), and two (10%) were of a combined type with a mixture of cystic degeneration and hemorrhagic necrosis. The remaining six tumors (23%)
showed increased CT attenuation after treatment, four of which showed abundant viable tumor cells on histological examination, one of which showed hemorrhagic necrosis with hypercellular viable portion, and the last one of which showed cystic and hyaline 18.8 ± 7.3 9-27 Small bowel (n = 5), peritoneum (n = 1), pelvic soft tissue (n = 1) Cystic change (n = 7)
12.0 ± 10.1 3-29 Liver (n = 4), small bowel (n = 1), stomach (n = 1), peritoneum (n = 1) Hyaline change (n = 6) 18.7 ± 9.1 6-30 Stomach (n = 2), liver (n = 2), peritoneum (n = 1), spleen (n = 1) Cystic + hemorrhagic (n = 2) 34.0 ± 14. 
